Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

BIO-TECHNE Corp (TECH)

As of 2026-11-19 · 12/15 boxes filled from SEC filings and market data

Report price $72.75 (close 2026-11-18); latest close $72.67 (2026-11-20), -0.1% since the report; figures re-marked at the latest close

Conclusion: AVOID

Conviction low · base case -56% · downside -65% · upside +5%

The market is not pricing Bio-Techne's earnings: at $72.75 the stock sits just under the $73.00 per-share Merck KGaA cash offer announced 2026-06-25 and approved by shareholders, so what is being paid for is the deal, not a 66.5x P/E on TTM net income to common against a 29.4x peer median. That is why the call is AVOID, with low conviction: the spread to the offer is merger-arbitrage return, not a fundamentals discount, and the business does not earn the price: revenue fell -0.4% in the fiscal year to 2026-06-30, ROIC of 7.9% sits below the 8.1% WACC, and the reverse DCF needs +10.7% revenue growth a year for ten years. The base case is $32.16 (-55.8%), on a P/E at 29.4x, the peer median P/E (4 peers in the comps table: RVTY 67.2x, A 34.7x, BIO 9.7x, QGEN 24.1x). The downside is $25.73 (-64.6%), on the base case's multiple on -20.0% earnings (the peers trade below the compressed multiple). The upside is $76.39 (+5.0%), on +5% earnings at today's P/E of 66.5x, which requires a bid above the agreed offer.

Key numbers

  • Share price: $72.67
  • Market cap: $11.42B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $1.23B
  • EV / EBITDA (TTM): 34.0x
  • P/E (TTM): 66.4x
  • FCF yield: 2.7%
  • Price / book: 5.27x
  • Earnings-quality flags (TTM): none flagged
  • EV / FCF (TTM): 37.2x
  • Revenue growth (latest fiscal year): -0.4%
  • ROIC (TTM): 7.9%
  • WACC: 8.1%
  • Economic profit spread: -0.1 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Bio-Techne is a two-segment life-science tools maker: Protein Sciences (approximately 72% of fiscal 2026 net sales) sells in-house manufactured proteins, antibodies, immunoassays and automated western-blot instruments, while Diagnostics and Spatial Biology (approximately 28%) sells OEM calibrators and controls plus spatial-biology assays and instruments. Revenue rose from $931.0M in fiscal 2021 to $1.22B in fiscal 2026 and $1.23B TTM to 2026-09-30, while operating income ran $298.9M in fiscal 2023, fell to $206.7M in fiscal 2024 and $102.3M in fiscal 2025, then recovered to $251.9M in fiscal 2026 and $240.8M TTM. Cash generation outruns reported earnings: operating cash flow was $292.1M in fiscal 2026 and $337.6M TTM against capex of only $28.9M and $29.4M. The portfolio has been reshaped by M&A (Lunaphore at the start of fiscal 2024; a 19.9% Wilson Wolf stake with the balance due by end-2027) and the second segment was renamed from Diagnostics and Genomics to Diagnostics and Spatial Biology. The company was formerly Techne Corporation and now files as Bio-Techne Corporation; filings under the earlier Techne name are its own.

  2. ✓ 2. Competitive advantage

    The moat is visible in gross margin, not in operating margin: gross profit ran between $632.9M (FY2021) and $807.6M (TTM to 2026-09-30) — roughly 68% of revenue in FY2021 and 65-66% in FY2026/TTM — while operating income swung from $298.9M (FY2023) to $102.3M (FY2025) and back to $251.9M (FY2026). The company claims world leadership in research-grade and cGMP proteins under brands R&D Systems, Tocris, Novus and ProteinSimple, manufactures in-house in North America, the U.K., Canada, Switzerland and China, and introduced over 1,900 new products in fiscal 2026. Competition is fragmented across product lines — the 10-K says no competitor offers all the same lines — and it names competitor categories, not companies, so competitive position is asserted rather than measured. Returns on book equity are modest ($181.8M net income to common on $2.11B total equity, FY2026), reflecting a balance sheet built by acquisition.

  3. ✓ 3. 10-Q takeaways

    Bio-Techne's first quarter of fiscal 2027 (quarter ended September 30, 2026) showed sales of $299.7 million, up 5% reported and 7% organic, with GAAP gross margin flat at 65.6% but adjusted gross margin down to 69.3% as SG&A rose 15%. Protein Sciences grew 9% with a 37.9% operating margin, while Diagnostics and Spatial Biology grew 1% and its operating margin fell to 7.4%. Cash was $350.0 million and first-quarter operating cash flow was $73.1 million, and the pending Merck KGaA merger was approved by shareholders on September 23, 2026. The 10-Q reports no material risk-factor changes from the FY2026 10-K.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans